Patents by Inventor Min-Guk HAN

Min-Guk HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies

Patent number: 11673965

Abstract: The present invention provides a pharmaceutical composition and a treatment method to be combined with radiotherapy, for treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 blockade and a PI3K? ? inhibitor, and it has excellent effects of inhibiting tumor and enhancing immunity by combining the PD-1 blockade and PI3K? ? inhibitor with radiotherapy, compared to single therapy of each therapeutic agent.

Type: Grant

Filed: July 6, 2020

Date of Patent: June 13, 2023

Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventors: In-Ah Kim, Min-Guk Han, Bum-Sup Jang, Mi-Hyun Kang, Won-Ick Chang
Method for treating triple negative breast cancer combined with radiotherapy comprising administering phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 blockade

Publication number: 20210198378

Abstract: The present invention provides a pharmaceutical composition and a treatment method to be combined with radiotherapy, for treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 blockade and a PI3K ? ? inhibitor, and it has excellent effects of inhibiting tumor and enhancing immunity by combining the PD-1 blockade and PI3K ? ? inhibitor with radiotherapy, compared to single therapy of each therapeutic agent.

Type: Application

Filed: July 6, 2020

Publication date: July 1, 2021

Inventors: In-Ah KIM, Min-Guk HAN, Bum-Sup JANG, Mi-Hyun KANG, Won-Ick CHANG

Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies

Method for treating triple negative breast cancer combined with radiotherapy comprising administering phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 blockade